You are about to exit signetglobal.com

Background pattern

Health Trends

Providing programmatic exposure to sector outperformance through investment in thematic, innovative healthcare platforms and companies.

Overview

Launched in [November 2021], the fund targets equity investments across three key trends: new biotech and pharma companies that are most likely to benefit from the most innovative drug development technologies; companies spearheading digital transformation of the healthcare industry; and companies driving the transformation of business models towards more efficient use of healthcare budgets and increasing personalization of patient care (so-called “precision medicine”). With monthly liquidity, the fund seeks a target return of 25% annualised over 5 years period with annualised volatility of 20%. The fund benefits from the insights of a scientific advisory board and is led by asset management specialists with decades of aggregate experiences in healthcare and scientific innovation investment.

Insights

Market and portfolio insights, webinars and podcasts from across our Health Trends Fund to provide our investors with the guidance they demand to navigate the changing world we are living in.

Insights - Outlook 2022 Health Care

Over the next 12 months, COVID-19 will continue to play a swing factor in the healthcare industry.

Group Overview - 2022

Discipline. Focus. Clarity. These are what set us apart. Rather than chase every fad, we hone in on...

Signet FFF Health Trends (CY) - 2022

The Fund targets equity investments across three key trends: new biotech and pharma companies most likely to benefit from the...

Documents

Market and portfolio insights, webinars and podcasts from across our investment teams.

By continuing, you confirm you have read and agree to the specified Policies and Legal Frameworks.

Meet the team

Natalia Kovalevskaya
Natalia Kovalevskaya Portfolio Manager Healthcare

Natalia joined Signet in 2020 as Investment Director taking part in managing and developing growing portfolio of healthcare investments in both private and public companies. She has extensive experience in deal sourcing, due diligence, valuation, and execution of life sciences investment opportunities as well as in managing and developing portfolios of biotechnology companies at various stages of development.

Prior to Signet, from 2017 Natalia focused on early-stage private life sciences companies in Europe working within entrepreneurial biotech ecosystem in Europe with academic start-ups and technology transfer offices and contributing to early-stage investment rounds. She also founded and actively fund raised for a seed fund dedicated to building early-stage life sciences ventures.

Prior to healthcare investing, Natalia was a Director at UBS Investment Bank from 2015 where she led structured financing transactions for institutional investors. Her expertise spans various financial products and asset classes with focus on global emerging markets. Her clients include extensive network of European institutional investors such as pension funds, hedge funds and real money asset managers. Natalia started her career in investment banking at Citi in London in 2009 on analyst graduate program and worked in Capital Markets Origination and Global Markets divisions moving on to VTB Capital in 2012.

Natalia holds a BSc in Biochemistry from Imperial College London, MSc Management with a focus on pharmaceutical industry from London School of Economics, and an MEng in Food Technology Engineering from Moscow State University of Applied Biotechnology.

Natalia is fluent in English, Russian, Italian, French and speaks conversational German.

Yiyi Jiang
Yiyi Jiang Senior Analyst

Yiyi Jiang is an Equity Analyst covering the healthcare sector at Signet Capital Management. Prior to joining Signet in 2021, Yiyi was a Senior Equity Analyst at HSBC Asset Management for more than six years covering Healthcare and Tech sectors in developed markets. Before that, she worked as Equity Analyst at Lombard Odier Asset Management and Strategic Investment Advisors. Following her BA in Finance from Renmin University, Yiyi completed her Masters in Economics from Yale University and PhD in Finance from IE Business School.

Robert Shore, PhD
Robert Shore, PhD Senior Analyst

Prior to joining Signet Management, Dr. Robert Shore was lead biotechnology analyst at Redburn, Europe’s largest
independent equity research shop. This followed several years as a postdoctoral research fellow in molecular biology at
Harvard Medical School, where he developed a model for the ZIKA virus through CRISPR gene editing. Robert holds an
MSc in Bioscience Technology, a PhD in Neurogenetics from the University of St Andrews’ School of Medicine and is
currently an MBA candidate at the University of Cambridge’s Judge Business School.

Serge Umansky
Serge Umansky Head of Health Trends

Serge Umansky is a Managing Director of Signet FFF Capital AG. He is a specialist in absolute return strategies with 12 years of experience in numerical analysis in engineering and over 25 years of investment and risk management. From 1977, he headed the research laboratory at the Ukranian Academy of Sciences in Kiev, focusing on numerical analysis and developing numerical models and software for aerospace applications. In 1989, he was hired by the Germany-based EWCO GmbH where he led implementation and support of financial management systems for corporate clients in Central Europe. In 1991, he joined WIR Corporation in the United States where he designed and developed computerised trading models and software tools for quantitative trading strategies. From 1993, he was appointed CIO of New Capital Markets in Washington, DC where he developed investment strategies, managed multi asset funds and designed proprietary portfolio management software. He then moved into a consultancy role with ICG consulting, L.L.C. for international debt restructuring advisory, private equity investments and research. In 1999, he joined Signet Research and Advisory as CIO where he was responsible for portfolio construction and investments selection, risk management, as well as quantitative and qualitative portfolio analysis. From 2016, he co-founded a number of Signet subsidiary advisory companies, Whiteridge Advisor SA in 2016 and Metadvice Limited in 2018. In January 2020, he was appointed CEO of Signet Capital Management Limited and acts as a head of Healthcare Investments team at Signet Global.